Engaging Innovation | Friends of Cancer Research

Engaging Innovation

Featured Post

December 10, 2018

Friends of Cancer Research Annual Meeting 2018

This year’s Friends of Cancer Research (Friends) Annual Meeting started with a morning keynote by Anna Abram the Deputy Commissioner for Policy, Planning, Legislation and Analysis at the U.S. Food and Drug Administration (FDA). Abram discussed many different initiatives that have been led by Friends over the years including the...
More Posts

Recent Posts

No Results With Current Filter Choices

Data Driven: Molecular Diagnostic Testing in Lung Cancer

Molecular diagnostics are central to the delivery of personalized cancer care. Without these important tools, physicians would not be able to select the appropriate patients for targeted therapy, negating the advantages conferred by recent advances in genomics. In the past fifteen years, there has been an explosion of new technologies to...

Data Driven: US Regulatory System Leads the World in New Drug Review Times

In the second installment of Data Driven, Friends of Cancer Research explores President Trump's claim that FDA's drug regulation impedes timely access to new medicines. We compared the time the FDA takes to review new cancer drugs with the time it takes European regulators to accomplish the same task.

Data Driven: Mining ClinicalTrials.gov – Institutions, Funding, and Areas of Focus

We thought it would be interesting to explore data from agencies whose work most closely impacts biomedical innovation, namely the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Centers for Medicare and Medicaid Services (CMS). In the first of a series, Friends investigated the NIH-sponsored site ClinicalTrials.gov. 

My Story: Stephanie Haney

Stephanie and her family were shocked by her diagnosis. She had no risk factors or family history. With the help of newly available treatments, such as breakthrough therapies, she has defied the odds.

My Story: Stephanie Haney

Stephanie and her family were shocked by her diagnosis. She had no risk factors or family history. With the help of newly available treatments, such as breakthrough therapies, she has defied the odds.

My Story: Stephanie Haney

Stephanie and her family were shocked by her diagnosis. She had no risk factors or family history. With the help of newly available treatments, such as breakthrough therapies, she has defied the odds.

My Story: Stephanie Haney

Stephanie and her family were shocked by her diagnosis. She had no risk factors or family history. With the help of newly available treatments, such as breakthrough therapies, she has defied the odds.

Back to Top